Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IM 23

Next Previous
Search
Drug Profile

IM 23

Alternative Names: IM23; IM23 CAR-T

Latest Information Update: 28 Aug 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Immunochina Medical Science and Technology
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Acute myeloid leukaemia

Most Recent Events

  • 28 Aug 2021 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(In adolescents, In children, In the elderly, Refractory metastatic disease, In adults) in China (Parenteral, Infusion)
  • 01 Oct 2020 Beijing Immunochina Medical Science & Technology completes a phase I trial in Acute myeloid leukaemia (In adults, In the elderly, In children, In adolescents, Refractory metastatic disease) in China (Parenteral) (NCT03585517)
  • 16 Jul 2018 Phase-I clinical trials in Acute myeloid leukaemia (In adults, In the elderly, In children, In adolescents, Refractory metastatic disease) in China (Parenteral) (NCT03585517)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top